Future Perspectives for Personalized Immunotherapy in Renal Cell Carcinoma

Expert Opinion on Biological Therapy - United Kingdom
doi 10.1080/14712598.2017.1339030
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2004English

Endogenous Retroviral Signatures Predict Immunotherapy Response in Clear Cell Renal Cell Carcinoma

Journal of Clinical Investigation
Medicine
2018English

Retraction: “Immunotherapy of Metastatic Renal Cell Carcinoma” by McDermott DF

Cancer
Cancer ResearchOncology
2019English

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives

Cancers
Cancer ResearchOncology
2011English

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Intratumoral Morphologic and Molecular Heterogeneity of Rhabd Renal Cell Carcinoma: Challenges for Personalized Therapy

Modern Pathology
Forensic MedicinePathology
2015English

Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

Benefit of Adjuvant Immunotherapy in Renal Cell Carcinoma: A Myth or a Reality?

PLoS ONE
Multidisciplinary
2017English

Personalized Therapy in Renal Cell Carcinoma: Are the Different Tyrosine Kinase Inhibitors the Same for Any Patient?

Expert Review of Precision Medicine and Drug Development
Molecular MedicineDrug DiscoveryGeneticsPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy